Mosaic Medical Technologies, Inc. Continues Growth

Mosaic Medical Technologies, Inc. (MMT) ( announced further additions to its staff at its Research & Development center in Sarasota.

Online PR News – 25-November-2010 – – SARASOTA, FLA. (November 19th, 2010)— Mosaic Medical Technologies, Inc. (MMT) ( announced further additions to its staff at its Research & Development center in Sarasota. The Company is pleased to announce hiring Eric Vandermeulen as its Clinical Research Manager. Mr. Vandermeulen is a biological engineer and will focus on development of the company’s biologically augmented device offering (Bio-Aug FX™). MMT is also pleased to bring Mike Dempsey onboard as its technical compliance manager. Mr. Dempsey oversees the company’s technical and engineering control systems as are required by the Food & Drug Administration (FDA).

Mosaic will be filing three patent applications in the fourth quarter as they pertain to intellectual property on Bio-Aug FX™ and ReSumo™ which is a non-fusion replacement spinal disc. Mosaic Medical Technologies is a wholly owned subsidiary of Global-Med Technologies Group (GTG), Inc. GTG’s CEO, M.G. Urbanski said, “we will continue to grow our research and development capabilities within Mosaic to advance the Company’s new product requirements. This is an area where we have an advantage over large companies which are lethargic in producing new products and often faced with a difficult business decision to obsolete their current inventory. We are excited about the potential for biologic applications in orthopaedics and expect significant market growth in that niche.”

GTG is a technologies-driven, research-based private holding group exclusively focused on the orthopaedic and musculoskeletal device sector. GTG provides surgeons and health professionals with clinically relevant, innovative and cost-effective products that improve the quality of life for patients. They focus on devices and procedures that are minimally invasive in nature and therefore, less traumatic to the patient. GTG’s subsidiary product lines include biologic, orthopaedic, spine, neurosurgical and other musculoskeletal devices and/or procedures that are indicated for repair, reconstruction and regeneration of bones, joints and surrounding soft tissues. The Company is researching and developing non-invasive procedures and treatments for osteoporosis and other age related degenerative diseases. It’s committed to the development of pre-operative, operative and post- operative procedures, devices and monitoring systems that reduce cost while providing surgeon and patient less traumatic surgical intervention options.

For more information, the GTG website is located at We are members of the Greater Sarasota Chamber of Commerce and the St. Armands Circle Association.